Head-To-Head Contrast: CAMP4 Therapeutics (NASDAQ:CAMP) & Genelux (NASDAQ:GNLX)

Genelux (NASDAQ:GNLX) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Profitability

This table compares Genelux and CAMP4 Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

Analyst Ratings

This is a breakdown of current ratings and target prices for Genelux and CAMP4 Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1	0	3	1	2.80
CAMP4 Therapeutics	1	1	6	0	2.62

Genelux presently has a consensus price target of $18.00, suggesting a potential upside of 593.91%. CAMP4 Therapeutics has a consensus price target of $9.79, suggesting a potential upside of 140.73%. Given Genelux’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Genelux is more favorable than CAMP4 Therapeutics.

Valuation & Earnings

This table compares Genelux and CAMP4 Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10,000.00	11,735.26	-$32.15 million	($0.86)	-3.02
CAMP4 Therapeutics	$3.50 million	72.88	-$80.40 million	($2.32)	-1.75

Genelux has higher earnings, but lower revenue than CAMP4 Therapeutics. Genelux is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Genelux has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, CAMP4 Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Institutional and Insider Ownership

37.3% of Genelux shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Genelux beats CAMP4 Therapeutics on 10 of the 15 factors compared between the two stocks.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.